Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$75.93 - $134.63
Previous CloseN/A
Volume3.30M
Average Volume (3M)17.84M
Market Cap
$197.26B
Enterprise Value$276.94B
Total Cash (Recent Filing)$8.24B
Total Debt (Recent Filing)$19.10B
Price to Earnings (P/E)11.6
Beta0.33
Next Earnings
Apr 24, 2025EPS Estimate
2.13Last Dividend Ex-Date
Mar 17, 2025Dividend Yield4.03%
Share Statistics
EPS (TTM)6.73
Shares Outstanding2,516,394,000
10 Day Avg. Volume18,365,340
30 Day Avg. Volume17,842,312
Financial Highlights & Ratios
PEG Ratio0.00254
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)17.00
P/FCF Ratio17.00
Enterprise Value/Market Cap1.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.34
Enterprise Value/Ebitda10.28
Forecast
1Y Price Target
$109.88Price Target Upside43.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Animal Health BusinessInvestors should be applying a higher multiple to stable revenue streams like the Animal Health business, which has no policy-related risk.
Phase 3 TrialsThe conditions are in place for a stock recovery as focus shifts to execution on Winrevair and upcoming data from three ongoing Phase 3 trials for its oral PCSK9 program.
Bears Say
Physician CautionUse in lower-risk PAH patients is still limited by physician caution regarding bleeding risk.
Vaccine UncertaintyA significant degree of vaccine-related uncertainty is already reflected in MRK shares, which could make the stock disproportionately sensitive to updates from other parts of the pharma business.
---
Ownership Overview
0.05% Insiders
21.26% Mutual Funds
0.79% Other Institutional Investors
54.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $75.93 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $197.26B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 24, 2025 which is in 6 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 04, 2025. The company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.609 by $0.111.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 4.03%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.13.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,516,394,000 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $1.72 in its last earnings report, beating expectations of $1.609. Following the earnings report the stock price went down -9.076%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$109.88 (43.71% Upside)
$109.88 (43.71% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 95%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $141.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.04%
12-Months-Change
Fundamentals
Return on Equity
40.81%
Trailing 12-Months
Asset Growth
9.78%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
---
MRK Company Deck
---
MRK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with strong performance in key areas like oncology and new product launches, but challenges persist with GARDASIL in China and impacts from Medicare Part D redesign. Although the company remains confident in its long-term growth potential, short-term headwinds are acknowledged.Read More>---
MRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$109.88
▲(43.71% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+4.42%
reiterated a buy rating 17 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +4.42% per trade.
---